• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

James D. Iglehart, MD


  • Bailey ST, Miron PL, Choi YJ, Kochupurakkal B, Maulik G, Rodig SJ, Tian R, Foley KM, Bowman T, Miron A, Brown M, Iglehart JD, Biswas DK.NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth.Mol Cancer Res. 2014 Mar;12(3):408-20.
  • Dreze M, Calkins AS, Gálicza J, Echelman DJ, Schnorenberg MR, Fell GL, Iwai S, Fisher DE, Szüts D, Iglehart JD, Lazaro JB.Monitoring repair of UV-induced 6-4-photoproducts with a purified DDB2 protein complex.PLoS ONE. 2014;9(1):e85896.
  • Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC.Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.PLoS ONE. 2013;8(11):e80023.
  • Calkins AS, Iglehart JD, Lazaro JB.DNA damage-induced inhibition of rRNA synthesis by DNA-PK and PARP-1.Nucleic Acids Res. 2013 Aug;41(15):7378-86.
  • Jeselsohn RM, Werner L, Regan MM, Fatima A, Gilmore L, Collins LC, Beck AH, Bailey ST, He HH, Buchwalter G, Brown M, Iglehart JD, Richardson A, Come SE.Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune response.PLoS ONE. 2013;8(5):e64225.
  • Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, Defazio A, Quackenbush J, Berkowitz RS, Iglehart JD, Bowtell DD, , Matulonis UA.Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome.Clin Cancer Res. 2012 Oct 15;18(20):5806-5815.
  • Dominici L, Liao GS, Brock J, Iglehart JD, Lotfi P, Meyer J, Pandalai P, Golshan M.Large Needle Core Biopsy of Atypical Ductal Hyperplasia: Results of Surgical Excision.Breast J. 2012 Aug 17.
  • Adelmant G, Calkins AS, Garg BK, Card JD, Askenazi M, Miron A, Sobhian B, Zhang Y, Nakatani Y, Silver PA, Iglehart JD, Marto JA, Lazaro JB.DNA ends alter the molecular composition and localization of Ku multicomponent complexes.Mol Cell Proteomics. 2012 Aug;11(8):411-21.
  • Utermark T, Rao T, Cheng H, Wang Q, Lee SH, Wang ZC, Iglehart JD, Roberts TM, Muller WJ, Zhao JJ.The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.Genes Dev. 2012 Jul 15;26(14):1573-86.
  • Richardson AL, Iglehart JD.BEAMing up personalized medicine: mutation detection in blood.Clin Cancer Res. 2012 Jun 15;18(12):3209-11.
  • Chittenden TW, Pak J, Rubio R, Cheng H, Holton K, Prendergast N, Glinskii V, Cai Y, Culhane A, Bentink S, Schwede M, Mar JC, Howe EA, Aryee M, Sultana R, Lanahan AA, Taylor JM, Holmes C, Hahn WC, Zhao JJ, Iglehart JD, Quackenbush J.Therapeutic implications of GIPC1 silencing in cancer.PLoS ONE. 2010;5(12):e15581.
  • Birdwell RL, Mountford CE, Iglehart JD.Molecular imaging of the breast.Radiol Clin North Am. 2010 Sep;48(5):1075-88.
  • Miron A, Varadi M, Carrasco D, Li H, Luongo L, Kim HJ, Park SY, Cho EY, Lewis G, Kehoe S, Iglehart JD, Dillon D, Allred DC, Macconaill L, Gelman R, Polyak K.PIK3CA mutations in in situ and invasive breast carcinomas.Cancer Res. 2010 Jul 15;70(14):5674-8.
  • Qiao M, Wang Y, Xu X, Lu J, Dong Y, Tao W, Stein J, Stein GS, Iglehart JD, Shi Q, Pardee AB.Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis.Mol Cell. 2010 May 28;38(4):512-23.
  • Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, Richardson AL, Wang ZC.Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer.Nat Med. 2010 Feb;16(2):214-8.
  • Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, Gown A, Hammond ME, Iglehart JD, Moench S, Pierce LJ, Ravdin P, Schnitt SJ, Wolff AC.NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.J Natl Compr Canc Netw. 2009 Sep;7 Suppl 6:S1-S21; quiz S22-3. Review.
  • Cheng H, Liu P, Wang ZC, Zou L, Santiago S, Garbitt V, Gjoerup OV, Iglehart JD, Miron A, Richardson AL, Hahn WC, Zhao JJ.SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis.Sci Signal. 2009;2(80):ra35.
  • Birdwell RL, Mountford CE, Iglehart JD.Molecular imaging of the breast.AJR Am J Roentgenol. 2009 Aug;193(2):367-76.
  • Iglehart JD, Silver DP.Synthetic lethality--a new direction in cancer-drug development.N Engl J Med. 2009 Jul 9;361(2):189-91.
  • Nunes RA,Li X,Kang SP,Burstein H,Roberts L,Carney W,Blackwell K,Ryan P,Borges V,Iglehart JD,Friedman P,Harris LN.Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy.Int J Biol Markers. 2009 Jan-Mar;24(1):1-10.
  • Dejmek J, Iglehart JD, Lazaro JB.DNA-dependent protein kinase (DNA-PK)-dependent cisplatin-induced loss of nucleolar facilitator of chromatin transcription (FACT) and regulation of cisplatin sensitivity by DNA-PK and FACT.Mol Cancer Res. 2009 Apr;7(4):581-91.
  • Rosner B,Colditz GA,Iglehart JD,Hankinson SE.Risk prediction models with incomplete data with application to prediction of estrogen receptor-positive breast cancer: prospective data from the Nurses' Health Study.Breast Cancer Res. 2008;10(4):R55.
  • Bafford AC,Burstein HJ,Barkley CR,Smith BL,Lipsitz S,Iglehart JD,Winer EP,Golshan M.Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival.Breast Cancer Res Treat. 2009 May;115(1):7-12. Review.
  • Lu X, Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL.Predicting features of breast cancer with gene expression patterns.Breast Cancer Res Treat. 2008 Mar;108(2):191-201.
  • Tamimi RM, Brugge JS, Freedman ML, Miron A, Iglehart JD, Colditz GA, Hankinson SE.Circulating colony stimulating factor-1 and breast cancer risk.Cancer Res. 2008 Jan 1;68(1):18-21.
  • Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR, Birdwell R, Lester S, Lipsitz S, Iglehart JD, Golshan M.Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy?.J Surg Oncol. 2007 Nov 1;96(6):474-80.
  • Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, Iglehart JD, Weinberg RA.Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes.Cancer Cell. 2007 Aug;12(2):160-70.
  • Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart JD, Biswas DK.Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer.Mol Cancer Ther. 2007 Jul;6(7):1973-82.
  • Qiao M, Iglehart JD, Pardee AB.Metastatic potential of 21T human breast cancer cells depends on Akt/protein kinase B activation.Cancer Res. 2007 Jun 1;67(11):5293-9.
  • Chan MM, Lu X, Merchant FM, Iglehart JD, Miron PL.Serial transplantation of NMU-induced rat mammary tumors: a model of human breast cancer progression.Int J Cancer. 2007 Aug 1;121(3):474-85.
  • Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP.Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.Clin Cancer Res. 2007 Feb 15;13(4):1198-207.
  • Chang SB, Miron P, Miron A, Iglehart JD.Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.J Surg Res. 2007 Mar;138(1):37-44.
  • Shi Q, Harris LN, Lu X, Li X, Hwang J, Gentleman R, Iglehart JD, Miron A.Declining plasma fibrinogen alpha fragment identifies HER2-positive breast cancer patients and reverts to normal levels after surgery.J Proteome Res. 2006 Nov;5(11):2947-55.
  • Biswas DK, Iglehart JD.Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer.J Cell Physiol. 2006 Dec;209(3):645-52. Review.
  • Ganesan S, Richardson AL, Wang ZC, Iglehart JD, Miron A, Feunteun J, Silver D, Livingston DM.Abnormalities of the Inactive X Chromosome Are a Common Feature of BRCA1 Mutant and Sporadic Basal-like Breast Cancer.Cold Spring Harb Symp Quant Biol. 2005;70:93-7.
  • Wang ZC, Buraimoh A, Iglehart JD, Richardson AL.Genome-Wide Analysis for Loss of Heterozygosity in Primary and Recurrent Phyllodes Tumor and Fibroadenoma of Breast using Single Nucleotide Polymorphism Arrays.Breast Cancer Res Treat. 2006 Jun;97(3):301-9.
  • Golshan M, Miron A, Nixon AJ, Garber JE, Cash EP, Iglehart JD, Harris JR, Wong JS.The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy.Am J Surg. 2006 Jul;192(1):58-62.
  • Wang ZC, Buraimoh A, Iglehart JD, Richardson AL.Genome-Wide Analysis for Loss of Heterozygosity in Primary and Recurrent Phyllodes Tumor and Fibroadenoma of Breast using Single Nucleotide Polymorphism Arrays.Breast Cancer Res Treat. 2006 Apr 27.
  • Zhang X, Lu X, Shi Q, Xu XQ, Leung HC, Harris LN, Iglehart JD, Miron A, Liu JS, Wong WH.Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data.BMC Bioinformatics. 2006;7:197.
  • Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S.X chromosomal abnormalities in basal-like human breast cancer.Cancer Cell. 2006 Feb;9(2):121-32.
  • Vansonnenberg E, Shankar S, Parker L, Cheung L, Morrison PR, Silverman SG, Igelhart D.Palliative radiofrequency ablation of a fungating, symptomatic breast lesion.AJR Am J Roentgenol. 2005 Mar;184(3 Suppl):S126-8.
  • Chan MM, Iglehart JD.Viral oncolysis: tumor-tailored therapy.Curr Surg. 2005 Jan-Feb;62(1):25-30.
  • Wang ZC, Lin M, Wei LJ, Li C, Miron A, Lodeiro G, Harris L, Ramaswamy S, Tanenbaum DM, Meyerson M, Iglehart JD, Richardson A.Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers.Cancer Res. 2004 Jan 1;64(1):64-71.
  • Nahta R, Iglehart JD, Kempkes B, Schmidt EV.Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol.Cancer Res. 2002 Apr 15;62(8):2267-71.
  • Bluman LG, Borstelmann NA, Rimer BK, Iglehart JD, Winer EP.Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ.J Womens Health Gend Based Med. 2001 Jul-Aug;10(6):589-98.
  • Harris LN, Yang L, Liotcheva V, Pauli S, Iglehart JD, Colvin OM, Hsieh TS.Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.Clin Cancer Res. 2001 Jun;7(6):1497-504.
  • Seth P, Lunetta KL, Bell DW, Gray H, Nasser SM, Rhei E, Kaelin CM, Iglehart DJ, Marks JR, Garber JE, Haber DA, Polyak K.Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer.Cancer Res. 2000 Dec 15;60(24):6859-63.
  • Davis PL, Miron A, Andersen LM, Iglehart JD, Marks JR.Isolation and initial characterization of the BRCA2 promoter.Oncogene. 1999 Oct 28;18(44):6000-12.
  • Parmigiani G, Berry DA, Winer EP, Tebaldi C, Iglehart JD, Prosnitz LR.Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis.J Clin Oncol. 1999 May;17(5):1465-73.
  • Bluman LG, Rimer BK, Berry DA, Borstelmann N, Iglehart JD, Regan K, Schildkraut J, Winer EP.Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2.J Clin Oncol. 1999 Mar;17(3):1040-6.
  • Elbendary AA, Cirisano FD, Evans AC, Davis PL, Iglehart JD, Marks JR, Berchuck A.Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells.Clin Cancer Res. 1996 Sep;2(9):1571-5.
  • Iglehart JD, Miron A, Rimer BK, Winer EP, Berry D, Shildkraut MJ.Overestimation of hereditary breast cancer risk.Ann Surg. 1998 Sep;228(3):375-84.
  • Davis PL, Shaiu WL, Scott GL, Iglehart JD, Hsieh TS, Marks JR.Complex response of breast epithelial cell lines to topoisomerase inhibitors.Anticancer Res. 1998 Jul-Aug;18(4C):2919-32.
  • Burke HB, Hoang A, Iglehart JD, Marks JR.Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma.Cancer. 1998 Mar 1;82(5):874-7.
  • Peters KG, Coogan A, Berry D, Marks J, Iglehart JD, Kontos CD, Rao P, Sankar S, Trogan E.Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis.Br J Cancer. 1998;77(1):51-6.
  • Lo JY, Baker JA, Kornguth PJ, Iglehart JD, Floyd CE.Predicting breast cancer invasion with artificial neural networks on the basis of mammographic features.Radiology. 1997 Apr;203(1):159-63.
  • Marks JR, Huper G, Vaughn JP, Davis PL, Norris J, McDonnell DP, Wiseman RW, Futreal PA, Iglehart JD.BRCA1 expression is not directly responsive to estrogen.Oncogene. 1997 Jan 9;14(1):115-21.
  • Vaughn JP, Stekler J, Demirdji S, Mills JK, Caruthers MH, Iglehart JD, Marks JR.Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides.Nucleic Acids Res. 1996 Nov 15;24(22):4558-64.
  • Davis P, Bazar K, Huper G, Lozano G, Marks J, Iglehart JD.Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.Oncogene. 1996 Sep 19;13(6):1315-22.
  • Vaughn JP, Davis PL, Jarboe MD, Huper G, Evans AC, Wiseman RW, Berchuck A, Iglehart JD, Futreal PA, Marks JR.BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells.Cell Growth Differ. 1996 Jun;7(6):711-5.
  • Vaughn JP, Iglehart JD, Demirdji S, Davis P, Babiss LE, Caruthers MH, Marks JR.Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay.Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8338-42.
  • Iglehart JD, Kerns BJ, Huper G, Marks JR.Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer.Breast Cancer Res Treat. 1995 Jun;34(3):253-63.
  • Futreal PA, Cochran C, Marks JR, Iglehart JD, Zimmerman W, Barrett JC, Wiseman RW.Mutation analysis of the THRA1 gene in breast cancer: deletion/fusion of the gene to a novel sequence on 17q in the BT474 cell line.Cancer Res. 1994 Apr 1;54(7):1791-4.
  • Marks JR, Humphrey PA, Wu K, Berry D, Bandarenko N, Kerns BJ, Iglehart JD.Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer.Ann Surg. 1994 Apr;219(4):332-41.
  • Kerns BJ, Jordan PA, Huper G, Marks JR, Iglehart JD, Layfied LJ.Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer.Mod Pathol. 1993 Nov;6(6):673-8.
  • Kerns BJ, Jordan PA, Moore MB, Humphrey PA, Berchuck A, Kohler MF, Bast RC, Iglehart JD, Marks JR.p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry.J Histochem Cytochem. 1992 Jul;40(7):1047-51.